Depression Treatment Market is expected to reach US$ 16.8 Bn by 2032 | FMI

 The Global Depression Treatment Market is expected to be worth US$ 16.8 billion by 2032, with a moderate CAGR of 5.2% from 2022 to 2032. The target market is predicted to be worth US$ 10.1 billion in 2022, up from US$ 9.7 billion in 2021.

Depression Treatment
Depression Treatment
Different factors like demographic changes, environmental conditions, and increasing mental stress are contributing to rising mental health disorders. The increasing prevalence of such disorders drives the growth of the depression treatment market over the forecast period.

Get Full Access @ https://www.futuremarketinsights.com/reports/depression-treatment-market

Escalating need for antidepressants and therapies to treat mental conditions is also expected to contribute to the target market growth. Governments across the world are endeavoring to increase the funding for mental health services, and the treatment of mental illness and depression disorders. Factors like the need for better quality treatments, affordable healthcare policies, funding and support from government organizations, and interventions of healthcare organizations for mental health disorders treatments also spur the growth of the depression treatment market.

“Rising awareness regarding mental health coupled with favorable initiatives by the government will propel the global growth of the depression treatment market over the forecast period,” says an FMI analyst.  

Key Takeaways:

·         Lack of specialists as well as associated social stigma may hinder market growth.

·         High prevalence of depressive disorders fuels the market growth in the U.S.

·         Germany’s depression treatment market will expand at 5.3% CAGR.

·         The depression treatment market in China will grow at a CAGR of 4.8%.

·         By disease, the depression segment is expected to register a CAGR of 5.3%.

·         Based on product, the drugs segment will grow at a CAGR of 5.2%.

Competitive Landscape 

Viatris (Mylan Pharmaceuticals Inc.), Sunovian Pharmaceuticals, AbbVie Inc. (Allergan, Inc.), Jubilant Generics Limited, Sanis Health Inc., Abbott Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceuticals, (Apotex Holdings, Inc.) Apotex Corporation, Alembic Pharmaceuticals Limited, Pfizer Inc., Cardinal Health, Hikma Pharmaceuticals, Zydus Lifesciences (Cadila), Cipla Ltd, Dr. Reddy’s Laboratories, Merck & Co., Eli Lily & Co., GlaxoSmithKline, Takeda Pharmaceuticals, BrainsWay Ltd., Nexstim Plc, Magstim Ltd., Neuronetics, Inc., Salience TMS Neuro Solutions, MagVenture, MAG & More GmbH, and Neurosoft, Ltd., among others are some of the major players in the depression treatment market profiled in the full version of the report.

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more